Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Published byῬεβέκκα Μακρής Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage."— Presentation transcript:

1 Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage of the population in TRITON-TIMI 38 (prasugrel) and PLATO (ticagrelor) studies, exploring effects... Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage of the population in TRITON-TIMI 38 (prasugrel) and PLATO (ticagrelor) studies, exploring effects of presence of diabetes and nature of management CV, cardiovascular; CVA, CV accident; MI, myocardial infarction; TIMI, thrombolysis in myocardial infarction. Jennifer A Rossington et al. Open Heart 2016;3:e000296 ©2016 by British Cardiovascular Society

Download ppt "Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage."

Similar presentations

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC 2008. Time (days) 5 10 15 0 050100150200250300350400.

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)
Discontinuation of medication after nonfatal event: MI

Discontinuation of medication after nonfatal event: MI
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Figure 1 Ischaemic endpoints

Figure 1 Ischaemic endpoints
LEADER trial: Primary Outcome

LEADER trial: Primary Outcome
PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)
The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor

The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor
TNT: Baseline and final LDL cholesterol levels

TNT: Baseline and final LDL cholesterol levels
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.

11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
Introduction Antiplatelet Agents ADP Receptor Antagonists.

Introduction Antiplatelet Agents ADP Receptor Antagonists.
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
FAERS death cases (all years) for NOACs versus warfarin.

FAERS death cases (all years) for NOACs versus warfarin.
Zuzana Motovska et al. JACC 2018;71:

Zuzana Motovska et al. JACC 2018;71:
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
The US Renal Data System “Pie Chart of Death”

The US Renal Data System “Pie Chart of Death”
Becker RC, et al. Lancet 2009;373:919-28

Becker RC, et al. Lancet 2009;373:919-28
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Similar presentations

Ads by Google